Mitigating sTNF/TNFR1 activation on VGluT2 + spinal cord interneurons improves immune function after mid-thoracic spinal cord injury
Brain, Behavior, and Immunity · 2025-01 · 123 · 633-643
DOI: 10.1016/j.bbi.2024.10.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, Behavior, and Immunity, 2025-01. Verfasst von Tetyana Martynyuk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Drexel University, Department of Biology, Philadelphia, PA, United States. Electronic address: tmartynyuk@rockefeller.edu. Hauptthemen laut MEDLINE: Spinal Cord Injuries, Interneurons, Vesicular Glutamate Transport Protein 2, Spinal Cord. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke, National Institutes of Health.
Abstract (Originalsprache)
Spinal cord injury (SCI) is a devastating condition with 250,000 to 500,000 new cases globally each year. Respiratory infections, e.g., pneumonia and influenza are the leading cause of death after SCI. Unfortunately, there is a poor understanding of how altered neuro-immune communication impacts an individual's outcome to infection. In humans and rodents, SCI leads to maladaptive changes in the spinal-sympathetic reflex (SSR) circuit which is crucial to sympathetic function. The cause of the impaired immune function may be related to harmful neuroinflammation which is detrimental to homeostatic neuronal function, aberrant plasticity, and hyperexcitable circuits. Soluble tumor necrosis factor (sTNF) is a pro-inflammatory cytokine that is elevated in the CNS after SCI and remains elevated for several months after injury. By pharmacologically attenuating sTNF in the CNS after SCI we were able to demonstrate improved immune function. Furthermore, when we investigated the specific cellular population which may be involved in altered neuro-immune communication we reported that excessive TNFR1 activity on excitatory INs promotes immune dysfunction. Furthermore, this observation is NF-kβ dependent in VGluT2 + INs. Our data is the first report of a target within the CNS, TNFR1, that contributes to SCI-induced immune dysfunction after T9-SCI and is a potential avenue for future therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drexel University, Department of Biology, Philadelphia, PA, United States. Electronic address: tmartynyuk@rockefeller.edu.
- Drexel University, Department of Biology, Philadelphia, PA, United States.
- Drexel University, Department of Neurobiology and Anatomy, Philadelphia, PA, United States.
- Drexel University, Department of Biology, Philadelphia, PA, United States; George Washington University, Department of Anatomy and Cell Biology, Washington, D.C., United States. Electronic address: jrb117@gwu.edu.
Förderung
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
- National Institutes of Health
Zitieren
APA
Martynyuk, T., Ricard, J., Bracchi-Ricard, V., Price, S., McGrath, J. R., Dougherty, K. J., Tom, V., & Bethea, J. R. (2025). Mitigating sTNF/TNFR1 activation on VGluT2 + spinal cord interneurons improves immune function after mid-thoracic spinal cord injury. Brain, Behavior, and Immunity, 123, 633-643. https://doi.org/10.1016/j.bbi.2024.10.021
Vancouver
Martynyuk T, Ricard J, Bracchi-Ricard V, Price S, McGrath JR, Dougherty KJ, et al. Mitigating sTNF/TNFR1 activation on VGluT2 + spinal cord interneurons improves immune function after mid-thoracic spinal cord injury. Brain, Behavior, and Immunity. 2025;123:633-643. doi:10.1016/j.bbi.2024.10.021
BibTeX
@article{Martynyuk2025,
author = {Martynyuk, Tetyana and Ricard, Jerome and Bracchi-Ricard, Valerie and Price, Samuel and McGrath, Jenna R and Dougherty, Kimberly J and Tom, Veronica and Bethea, John R},
title = {Mitigating sTNF/TNFR1 activation on VGluT2 + spinal cord interneurons improves immune function after mid-thoracic spinal cord injury},
journal = {Brain, Behavior, and Immunity},
year = {2025},
volume = {123},
pages = {633--643},
doi = {10.1016/j.bbi.2024.10.021}
}
EUVIMED